Meeting
2023 ASCO Quality Care Symposium
Understanding testing for and treatment of homologous recombination repair (HRR)-mutated metastatic castrate-resistant prostate cancer (mCRPC): A quality initiative by Integra Connect PrecisionQ.
Authors
Roby Antony Thomas
University of Pittsburgh Medical Center, Pittsburgh, PA
Roby Antony Thomas, Simon Blanc, Mike Gart, Rushir J. Choksi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Health Care Access, Equity, and Disparities,Technology and Innovation in Quality of Care,Palliative and Supportive Care
Sub Track
Use of IT/Analytics to Improve Quality
Citation
JCO Oncol Pract 19, 2023 (suppl 11; abstr 581)
DOI
10.1200/OP.2023.19.11_suppl.581
Abstract #
581
Poster Bd #
N4
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Real world (rw) homologous recombination repair (HRR) gene mutation testing trends in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the United States (US).
First Author: Pedro C. Barata
Poster
2022 ASCO Genitourinary Cancers Symposium
ADAM: A multicenter, non-interventional, prospective cohort study for determination of prevalence of homologous recombination repair genes mutations (HRRm) in metastatic castrate resistant prostate cancer (mCRPC)—Interim analysis.
First Author: Boris Alexeev
Poster
2021 ASCO Annual Meeting
Differential responses to taxanes and PARP inhibitors (PARPi) in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer (mCRPC) patients (pts).
First Author: Christopher T Su
Poster
2020 ASCO Virtual Scientific Program
Association of BRCA alteration (alt) type with real-world (RW) outcomes to PARP inhibitors (PARPi) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Emmanuel S. Antonarakis